Combined therapy using bevacizumab and turmeric ethanolic extract (with absorbable curcumin) exhibited beneficial efficacy in colon cancer mice

Pharmacological Research

Volumn 111, Issue , 2016, Pages 43-57

  Yue, Grace Gar Lee ^a   Kwok, Hin Fai ^a   Lee, Julia Kin Ming ^a   Jiang, Lei ^a   Wong, Eric Chun Wai ^a   Gao, Si ^a   Wong, Hing Lok ^a   Li, Lin ^a   Chan, Kar Man ^a   Leung, Ping Chung ^a   Fung, Kwok Pui ^a   Zuo, Zhong ^a   Lau, Clara Bik San ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bevacizumab; Colorectal cancer; Curcumin; Turmeric; Turmerone

Indexed keywords

BEVACIZUMAB; CURCUMIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TURMERIC; TURMERONE; ALCOHOL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PLANT EXTRACT; SOLVENT; TURMERIC EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; ANIMAL; BAGG ALBINO MOUSE; BIOAVAILABILITY; CELL PROLIFERATION; CHEMISTRY; COLON TUMOR; COMPARATIVE STUDY; CURCUMA; DRUG EFFECTS; DRUG SCREENING; GASTROINTESTINAL ABSORPTION; HT-29 CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BEVACIZUMAB; BIOLOGICAL AVAILABILITY; CELL PROLIFERATION; COLONIC NEOPLASMS; CURCUMA; CURCUMIN; ETHANOL; GASTROINTESTINAL ABSORPTION; HT29 CELLS; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS; SOLVENTS; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84974593776     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.05.025     Document Type: Article

References (43)

1. GLOBOCAN Cancer Fact Sheets 2015 (accessed 01.11.15) http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
2. B.B. Aggarwal, and S. Shishodia Molecular targets of dietary agents for prevention and therapy of cancer Biochem. Pharmacol. 71 2006 1397 1421
3. K.M. Mohandas, and D.C. Desai Epidemiology of digestive tract cancers in India. V. Large and small bowel Indian J. Gastroenterol. 18 1999 118 121
4. D.P. Chauhan Chemotherapeutic potential of curcumin for colorectal cancer Curr. Pharm. Des. 8 2002 1695 1706
5. A. Goel, A.B. Kunnumakkara, and B.B. Aggarwal Curcumin as Curecumin: from kitchen to clinic Biochem. Pharmacol. 75 2008 787 809
6. S. Prasad, A.K. Tyagi, and B.B. Aggarwal Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice Cancer Res. Treat. 46 2014 2 18
7. P. Anand, A.B. Kunnumakkara, R.A. Newman, and B.B. Aggarwal Bioavailability of curcumin: problems and promises Mol. Pharm. 4 2007 807 818
8. G. Garcea, D.P. Berry, D.J. Jones, R. Singh, and et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences Cancer Epidemiol. Biomarkers Prev. 14 2005 120 125
9. S.C. Gupta, S. Patchva, and B.B. Aggarwal Therapeutic roles of curcumin: lessons learned from clinical trials AAPS J. 15 2013 195 218
10. B. Antony, B. Merina, V.S. Iyer, N. Judy, and et al. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax). a novel bioenhanced preparation of curcumin J. Pharm. Sci. 70 2008 445 449
11. B.B. Aggarwal, W. Yuan, S. Li, and S.C. Gupta Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: identification of novel components of turmeric Mol. Nutr. Food Res. 57 2013 1529 1542
12. G.G.L. Yue, S.W. Cheng, H. Yu, Z.S. Xu, and et al. The role of turmerones on curcumin transportation and P-glycoprotein activities in intestinal Caco-2 cells J. Med. Food 15 2012 242 252
13. G.G.L. Yue, L. Jiang, H.F. Kwok, J.K.M. Lee, and et al. Turmeric ethanolic extract possesses stronger inhibitory activities on colon tumor growth than curcumin - the importance of turmerones J. Funct. Foods 22 2016 565 577
14. Y. Yu, S.S. Kanwar, B.B. Patel, J. Nautiyal, and et al. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX Trans. Oncol. 2 2009 321 328
15. G.P. Hess, P.F. Wang, D. Quach, B. Barber, and Z. Zhao Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice J. Oncol. Pract. 6 2010 301 307
16. S.Y. Zafar, J.E. Marcello, J.L. Wheeler, K.L. Rowe, and et al. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer J. Oncol. Pract. 5 2009 228 233
17. D. Alishekevitz, R. Bril, D. Loven, V. Miller, and et al. Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing Mol. Cancer Ther. 13 2014 202 213
18. B.B. Patel, D. Gupta, A.A. Elliott, V. Sengupta, and et al. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R Anticancer Res. 30 2010 319 325
19. L. Li, B. Ahmed, K. Mehta, and R. Kurzrock Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer Mol. Cancer Ther. 6 2007 1276 1282
20. A.B. Kunnumakkara, P. Diagaradjane, P. Anand, K.B. Harikumar, and et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model Int. J. Cancer 125 2009 2187 2197
21. C. Kantara, M. O'Connell, S. Sarkar, S. Moya, and et al. Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA Cancer Res. 74 2014 2487 2498
22. J. Ravindran, S. Prasad, and B.B. Aggarwal Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 11 2009 495 510
23. G.G.L. Yue, H.F. Kwok, J.K.M. Lee, L. Jiang, and et al. Novel anti-angiogenic effects of aromatic-turmerone, essential oil isolated from spice turmeric J. Funct. Foods 15 2015 243 253
24. C.P. Commission Chinese Pharmacopoeia 2015 Commercial Press Shanghai
25. L. Zhongfa, M. Chiu, J. Wang, W. Chen, and et al. Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice Cancer Chemothe.r Pharmacol. 69 2012 679 689
26. S.K. Vareed, M. Kakarala, M.T. Ruffin, J.A. Crowell, and et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects Cancer Epidemiol. Biomarkers Prev. 17 2008 1411 1417
27. A. Asai, and T. Miyazawa Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma Life Sci. 67 2000 2785 2793
28. S. Priego, F. Feddi, P. Ferrer, S. Mena, and et al. Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism Mol. Cancer Ther. 7 2008 3330 3342
29. M. Yanagisawa, K. Fujimoto-Ouchi, K. Yorozu, Y. Yamashita, and K. Mori Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models Oncol. Rep. 22 2009 241 247
30. J. Jiang, Y. Zhang, S. Chuai, Z. Wang, and et al. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype Oncogene 31 2012 671 682
31. G.G.L. Yue, J.K. Lee, H.F. Kwok, L. Cheng, and et al. Novel PI3K/AKT targeting anti-angiogenic activities of 4-vinylphenol, a new therapeutic potential of a well-known styrene metabolite Sci. Rep. 5 2015 11149
32. D. Subramaniam, R. May, S.M. Sureban, K.B. Lee, and et al. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity Cancer Res. 68 2008 1962 1969
33. D. Wang, C.R. Stockard, L. Harkins, P. Lott, and et al. Immunohistochemistry in the evaluation of neovascularization in tumor xenografts Biotechnol. Histochem. 83 2008 179 189
34. D. Bordoloi, N.K. Roy, J. Monisha, G. Padmavathi, and A.B. Kunnumakkara Multi-Targeted agents in cancer cell chemosensitization: what we learnt from curcumin thus far Recent Pat Anticancer Drug Discov. 11 2016 67 97
35. G.G.L. Yue, B.C. Chan, P.M. Hon, M.Y. Lee, and et al. Evaluation of in vitro anti-proliferative and immunomodulatory activities of compounds isolated from Curcuma longa Food Chem. Toxicol. 48 2010 2011 2020
36. G.G.L. Yue, B.C. Chan, P.M. Hon, E.J. Kennelly, and et al. Immunostimulatory activities of polysaccharide extract isolated from Curcuma longa Int. J. Biol. Macromol. 47 2010 342 347
37. M.H. Pan, T.M. Huang, and J.K. Lin Biotransformation of curcumin through reduction and glucuronidation in mice Drug Metab. Dispos. 27 1999 486 494
38. H. Yu, and Q. Huang Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions J. Agric. Food. Chem. 60 2012 5373 5379
39. R.C. Martin, H.S. Aiyer, D. Malik, and Y. Li Effect on pro-inflammatory and antioxidant genes and bioavailable distribution of whole turmeric vs curcumin: similar root but different effects Food Chem. Toxicol. 50 2012 227 231
40. J.Z. Gao, J.L. Du, Y.L. Wang, J. Li, and et al. Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma Oncol. Lett. 9 2015 295 299
41. Z. Zhong, W. Tan, X. Chen, and Y. Wang Furanodiene, a natural small molecule suppresses metastatic breast cancer cell migration and invasion in vitro Eur. J. Pharmacol. 737 2014 1 10
42. A.K. Tyagi, S. Prasad, W. Yuan, S. Li, and B.B. Aggarwal Identification of a novel compound (beta-sesquiphellandrene) from turmeric (Curcuma longa) with anticancer potential: comparison with curcumin Invest. New Drugs 33 2015 1175 1186
43. M.I. James, C. Iwuji, G. Irving, A. Karmokar, and et al. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy Cancer Lett. 364 2015 135 141